RNXT - RenovoRx Inc Company Long-Term Liabilities

The daily price chart for RenovoRx, Inc. (RNXT) is accompanied by compliance with environmental standards for polymer disposal. Business revenues will be based on the market launch of Renovo-Cath for precise drug delivery into tumors, where the metric is 0.00. RenovoRx, Inc. (RNXT) technology, RenovoTAMP, minimizes toxic impact on the body, significantly increasing chemotherapy effectiveness through localized drug delivery.

This indicator aggregates total liabilities with maturities exceeding one year, allowing for an assessment of the debt load and capital resilience against macroeconomic shocks. By analyzing the history of the firm's long-term borrowings, an investor can identify default risks for RenovoRx, Inc. (RNXT), whose early-stage clinical trials and lack of revenue make the company critically dependent on external financing as liquidity depletes.